SCHEMBL20816097

SCHEMBL20816097

O=C(O)C(Cc1c[nH]c2ccccc12)NI

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.67
ACE P12821 3/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
KDM4E B2RXH2 2/20 0.63
MAPT P10636 2/20 0.63
APAF1 O14727 1/20 0.63
POLB P06746 1/20 0.63
RECQL P46063 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MEN1 O00255 1/20 0.63
LMNA P02545 1/20 0.63
MPO P05164 1/20 0.63
TSHR P16473 1/20 0.63
BLM P54132 1/20 0.63
PMP22 Q01453 1/20 0.63
KMT2A Q03164 1/20 0.63
HIF1A Q16665 1/20 0.63
ITGB2 P05107 3/20 0.62
ICAM1 P05362 3/20 0.62
ITGAL P20701 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29429240 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL18830959 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL29429239 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL30782236 0.88 ALOX15 (0.70) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL19090900 0.87 ECE1 (0.61) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170878 0.87 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL2167226 0.87 ALOX15 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170877 0.87 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL1755294 0.87 ALOX15 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL15226899 0.86 ALOX15 (0.64) ALOX15ACESMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747882-A1 DATA STORAGE USING PROTEINS The Hong Kong Polytechnic University (CN) 2026-05-27 EP disclosed
WO-2025015598-A1 DATA STORAGE USING PROTEINS THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2025-01-23 WO disclosed
WO-2024081692-A1 MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2024-04-18 WO disclosed
US-11692003-B2 Mithramycin derivatives having increased selectivity and anti-cancer activity UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2023-07-04 US disclosed
US-20230132854-A1 MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 US disclosed
US-11302421-B2 Data storage using peptides THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2022-04-12 US disclosed
US-20220033429-A1 MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNITED STATES GOVERNMENT 2022-02-03 US disclosed
US-11224609-B2 Mithramycin derivatives having increased selectivity and anti-cancer activity UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2022-01-18 US disclosed
US-20210090688-A1 Data storage using peptides THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2021-03-25 US disclosed
US-20200131218-A1 MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2020-04-30 US disclosed
US-20190083519-A1 MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNITED STATES GOVERNMENT 2019-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11692003-B2 Mithramycin derivatives having increased selectivity and anti-cancer activity MELK, TFAM, MDK ALOX15 3784/4885ACE 3315/4885SMN1; SMN2 510/4885
US-20220033429-A1 MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY MELK, TFAM, MDK ALOX15 3784/4885ACE 3315/4885SMN1; SMN2 510/4885
US-20230132854-A1 MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY TFAM, HSPE1, PRDX3 ALOX15 1150/4885ACE 3596/4885SMN1; SMN2 197/4885
US-11224609-B2 Mithramycin derivatives having increased selectivity and anti-cancer activity TFAM, ELF3, TEAD4 ALOX15 4576/4885ACE 2523/4885SMN1; SMN2 460/4885
US-20200131218-A1 MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY HMOX1, HSPE1, TFAM ALOX15 1015/4885ACE 1853/4885SMN1; SMN2 608/4885
US-20190083519-A1 MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY TFAM, ELF3, TEAD4 ALOX15 4576/4885ACE 2523/4885SMN1; SMN2 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.